More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion.
更多的利妥昔单抗组的患者在第一次注射后发生不良反应,大多数都是1或2级的。
More patients in the rituximab group than in the placebo group had adverse events, mostly grade 1 or grade 2, after the first infusion.
更多的利妥昔单抗组的患者在第一次注射后发生不良反应,大多数都是1或2级的。
应用推荐